BR112021025105A2 - Métodos e composições para melhorar os resultados de pacientes com câncer - Google Patents

Métodos e composições para melhorar os resultados de pacientes com câncer

Info

Publication number
BR112021025105A2
BR112021025105A2 BR112021025105A BR112021025105A BR112021025105A2 BR 112021025105 A2 BR112021025105 A2 BR 112021025105A2 BR 112021025105 A BR112021025105 A BR 112021025105A BR 112021025105 A BR112021025105 A BR 112021025105A BR 112021025105 A2 BR112021025105 A2 BR 112021025105A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical grade
methods
compositions
buffering agent
patient
Prior art date
Application number
BR112021025105A
Other languages
English (en)
Inventor
David Denomme Brian
Johanness Pertrus Van Wyk Hendrik
James Ervin
Luise Van Wyk Mariette
A Volk Michael
Maria Pizzimenti Natalie
B Lange Peter
Peter Pacult
Original Assignee
Reven Ip Holdco Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reven Ip Holdco Llc filed Critical Reven Ip Holdco Llc
Publication of BR112021025105A2 publication Critical patent/BR112021025105A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

métodos e composições para melhorar os resultados de pacientes com câncer. esta revelação fornece composições e métodos para melhorar os resultados em pacientes com câncer. especificamente, método para prevenir, aliviar ou tratar o câncer, caracterizado pelo fato de compreender a administração de quantidade eficaz de composição ao paciente dela necessitado, em que a composição compreende pelo menos um ácido de grau farmacêutico e pelo menos um agente tamponante de ph de grau farmacêutico em solução aquosa estéril, cujas concentrações do ácido de grau farmacêutico e do agente tamponante de ph de grau farmacêutico na solução tampão é suficiente para fornecer teor total de ácido titulável entre 60 mmol/l e 3000 mmol/l quando administrado ao paciente, e em que a seleção do ácido de grau farmacêutico e do agente tamponante de ph de grau farmacêutico é eficaz para fornecer ph de solução tampão entre 4,0 e 7,7.
BR112021025105A 2019-06-12 2020-06-12 Métodos e composições para melhorar os resultados de pacientes com câncer BR112021025105A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962860642P 2019-06-12 2019-06-12
PCT/US2020/037398 WO2020252238A1 (en) 2019-06-12 2020-06-12 Methods and compositions for improving outcomes of cancer patients

Publications (1)

Publication Number Publication Date
BR112021025105A2 true BR112021025105A2 (pt) 2022-03-15

Family

ID=73745688

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025105A BR112021025105A2 (pt) 2019-06-12 2020-06-12 Métodos e composições para melhorar os resultados de pacientes com câncer

Country Status (14)

Country Link
US (1) US20200390743A1 (pt)
EP (1) EP3982947A1 (pt)
JP (1) JP2022536708A (pt)
KR (1) KR20220029657A (pt)
CN (1) CN114222566A (pt)
AR (1) AR120059A1 (pt)
AU (1) AU2020293232A1 (pt)
BR (1) BR112021025105A2 (pt)
CA (1) CA3141418A1 (pt)
EA (1) EA202290027A1 (pt)
IL (1) IL288787A (pt)
MX (1) MX2021015228A (pt)
TW (1) TW202112358A (pt)
WO (1) WO2020252238A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190083527A1 (en) 2017-09-15 2019-03-21 Ampersand Biopharmaceuticals, Inc. Method of administration and treatment
US20230135127A1 (en) * 2021-10-28 2023-05-04 Wei-ping Zeng Compositions and methods for disease treatment and prevention by ph modifiers and/or cell proliferation inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135948A (en) * 1988-11-21 1992-08-04 Norsk Hydro A.S. Pharmaceutical compositions with anti-cancer activity against carcinoma and method for the treatment of carcinoma
EP1191948A2 (en) * 1999-06-11 2002-04-03 Neorx Corporation High dose radionuclide complexes for bone marrow suppression
US20040110684A1 (en) * 1999-08-02 2004-06-10 Universite Catholique De Louvain Novel pharmaceutical compositions for modulating angiogenesis
WO2005044176A2 (en) * 2003-11-10 2005-05-19 Lipogen Ltd. Compositions containing phosphatidic acid, methods of use thereof, methods of manufacture thereof, and articles of manufacture containing same
CU23432B6 (es) * 2005-11-02 2009-10-16 Ct Ingenieria Genetica Biotech Formulaciones estabilizadas que contienen a los interferones gamma y alfa en proporciones potenciadoras
PL2109608T3 (pl) * 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
WO2008100591A2 (en) * 2007-02-14 2008-08-21 The General Hospital Corporation Modulation of nitric oxide signaling to normalize tumor vasculature
AU2011280985C1 (en) * 2010-07-22 2016-04-21 Reven Pharmaceuticals, Inc. Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
JP6554099B2 (ja) * 2013-08-07 2019-07-31 イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． ｐ５３変異体を再活性化することの可能なペプチド

Also Published As

Publication number Publication date
WO2020252238A1 (en) 2020-12-17
AR120059A1 (es) 2022-02-02
AU2020293232A1 (en) 2022-02-03
CA3141418A1 (en) 2020-12-17
IL288787A (en) 2022-02-01
MX2021015228A (es) 2022-02-10
TW202112358A (zh) 2021-04-01
EP3982947A1 (en) 2022-04-20
KR20220029657A (ko) 2022-03-08
CN114222566A (zh) 2022-03-22
EA202290027A1 (ru) 2022-03-29
US20200390743A1 (en) 2020-12-17
JP2022536708A (ja) 2022-08-18

Similar Documents

Publication Publication Date Title
BR112021025105A2 (pt) Métodos e composições para melhorar os resultados de pacientes com câncer
US6159944A (en) Method for treating painful conditions of the anal region and compositions therefor
US8303994B2 (en) Method for the eradication of pathogens including S. aureus and antibiotic resistant microbes from the upper respiratory tract of mammals and for inhibiting the activation of immune cells
BR112018016341A2 (pt) solução de bloqueio do cateter e terapia de bloqueio do cateter
BRPI0810118A8 (pt) Método para tratar doença, método para efetuar profilaxia contra caa, uso de um agente, método para reduzir amilóide vascular em um paciente, e, kit para tratamento
AR047779A1 (es) Composiciones y metodos para tratar diabetes
BR112023001956A2 (pt) Composto de fórmula (ia), (ib), (ic) ou (ii), composição farmacêutica, composto para uso ou composição farmacêutica para uso em um método de tratamento de câncer
Mongardon et al. Impact of late administration of corticosteroids in COVID-19 ARDS
Galica et al. Intrathecal trialing of continuous infusion combination therapy with hydromorphone and bupivacaine in failed back surgery patients
CO2024012870A2 (es) Tratamiento de neurofibromas cutáneos con mirdametinib
BR112022021640A2 (pt) Usos e formulações de canabinoides
BR112023024741A2 (pt) Composto de quinolinamina, método de preparação para o mesmo e aplicação do mesmo em produtos farmacêuticos
BR122021012549B8 (pt) Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva
Cimetti et al. How to perform intravenous regional limb perfusion using amikacin and DMSO
BR112023000631A2 (pt) Dispositivo de administração de agente, sistema de administração de agente e método para administrar um agente
WO2015024420A1 (zh) 局麻药止痛延时剂
BR112022022452A2 (pt) Inibidores de il4i1 e métodos de uso
BR112022014456A2 (pt) Tafoxiparina para o tratamento da pré-eclâmpsia
BRPI0409387B8 (pt) complexo de alvejamento de tecido mole de tório-227 e um agente complexante, uso do mesmo, composição farmacêutica, método para a formação de um complexo, e, kit para uso em um método para o tratamento de doença de tecido mole em um indivíduo mamífero
Akbaş et al. Does intravenous tranexamic acid reduce blood loss during surgically assisted rapid palatal expansion?
Suriadi et al. Case report on the use of a honey on diabetic foot ulcer patients
Miller et al. A comparison of the efficacy of injectable dexamethasone sodium phosphate versus placebo in postoperative podiatric analgesia
Gericke et al. Percutaneous intra-articular tranexamic acid following total knee arthroplasty without drainage to reduce blood loss
Boychuk-Tovsta et al. Clinical evaluation of 0, 2% hyaluronic acid containing gel “gengigel” in the local treatment of pregnant women with generalized periodontitis on the background of IDA
Yadav et al. Comparison of dexmedetomidine and dexamethasone as an adjuvant to bupivacaine in supraclavicular block

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2750 DE 19/09/2023.